Chronic lung allograft rejection: mechanisms and therapy.

@article{Belperio2009ChronicLA,
  title={Chronic lung allograft rejection: mechanisms and therapy.},
  author={John A Belperio and S Samuel Weigt and Michael C. Fishbein and Joseph P. Iii Lynch},
  journal={Proceedings of the American Thoracic Society},
  year={2009},
  volume={6 1},
  pages={
          108-21
        }
}
Lung transplantation is a therapeutic option for patients with end-stage pulmonary disorders. Unfortunately, due to post-lung transplant complications, both infectious and noninfectious, it is only a treatment and not a cure. Importantly, despite induction combined with triple or quadruple maintenance immunosuppressive therapy, chronic lung rejection, in the form of obliterative bronchiolitis or its clinical correlate bronchiolitis obliterans syndrome (BOS), continues to be highly prevalent and… 

Figures and Tables from this paper

Pediatric Lung Transplantation
TLDR
The postoperative period is not only crucial for early detection of complications, such as infections and rejection, but also in the long term when gastrointestinal and neurological complications may compromise up to 50% of the patients.
Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review
TLDR
In a large multicentre randomised trial, pirfenidone did not appear to have a beneficial effect on lung function decline in established bronchiolitis obliterans syndrome, and continuation of antifibrotic treatment during waiting time for lung transplantation proved to be safe.
Diagnosis, Pathophysiology and Experimental Models of Chronic Lung Allograft Rejection
TLDR
The pathological hallmarks of chronic rejection, recent insights gained from both clinical and basic science research, and the current state of animal models of chronic lung rejection are explored.
Considerations for Lung Transplantation in Patients With Idiopathic Pulmonary Fibrosis
TLDR
Idiopathic pulmonary fibrosis patients have worse survival after lung transplant, at least in part due to early mortality, but it remains a mainstay of therapy given the lack of effective alternatives.
Targeting Allograft Injury and Inflammation in the Management of Post‐Lung Transplant Bronchiolitis Obliterans Syndrome
  • A. Robertson, S. Griffin, C. Ward
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2009
TLDR
This review deals with nonalloimmune factors that may potentiate alloimmune injury and infection and reflux/aspiration as examples of allograft injury, which may lead to chronic loss of graft function and BOS.
Preliminary Report on the Effect of Mesenchymal Stem Cell Therapy in Patients with Chronic Lung Allograft Dysfunction
  • C. Keller
  • Medicine
    Journal of Stem Cell Therapy and Transplantation
  • 2018
TLDR
Long-term survival of lung transplant recipients is compromised by chronic lung allograft dysfunction (CLAD), either obstructive (or bronchiolitis obliterans syndrome [BOS]) or restrictive (restrictive allografted syndrome) [8].
An Unwelcome Guest: Aspergillus Colonization in Lung Transplantation and Its Association with Bronchiolitis Obliterans Syndrome
  • S. Garantziotis, S. Palmer
  • Medicine, Biology
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2009
TLDR
A clear association of Aspergillus colonization with the subsequent onset of BOS is shown, with colonization being an independent predictor of morbidity and mortality due to BOS regardless of acute rejection scores.
Biomarkers of pulmonary rejection.
[Predictors for the Bronchiolitis Obliterans Syndrome in Lung Transplant Patient].
TLDR
The current state of knowledge on predictors for bronchiolitis obliterans syndrome is reviewed, which is regarded as a fibrosing process in the small airways leading to irreversible airway obstruction.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 184 REFERENCES
Chronic allograft rejection (obliterative bronchiolitis).
  • G. Verleden
  • Medicine
    Seminars in respiratory and critical care medicine
  • 2001
TLDR
The current knowledge of chronic rejection after heart-lung and lung transplantation is reviewed, and a clinical grading system has been proposed, divided into four and, more recently, five categories, depending on the severity of airflow obstruction.
Bronchiolitis obliterans syndrome complicating lung or heart-lung transplantation.
TLDR
A greater understanding of the pathogenic mechanisms operative in BOS are critical to developing novel strategies to treat and prevent this devastating complication.
Acute and chronic rejection after lung transplantation.
Over the last decade, improvements in surgical techniques, lung preservation, immunosuppression, and management of ischemia-reperfusion injury and infections have contributed to increase the 1 year
Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS).
  • A. Fisher, J. Wardle, J. Dark, P. Corris
  • Medicine
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • 2002
Early experience with sirolimus in lung transplant recipients with chronic allograft rejection.
  • B. Cahill, K. T. Somerville, S. Karwande
  • Medicine
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • 2003
Minimal Acute Rejection after Lung Transplantation: A Risk for Bronchiolitis Obliterans Syndrome
  • A. P. Khalifah, R. Hachem, M. Walter
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2005
TLDR
It is concluded that minimal rejection is associated with an increased risk for BOS development and progression that is comparable to A2 rejection.
Pathologic correlates of bronchiolitis obliterans syndrome in pulmonary retransplant recipients.
TLDR
It is concluded that significant histologic heterogeneity exists among patients undergoing retransplantation for BOS, potentially contributing to the variability of patient responses to treatment.
Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management.
Analysis of risk factors for the development of bronchiolitis obliterans syndrome.
TLDR
Analysis of the current data leads us to believe that LBB, in the absence of infection, is in fact a manifestation of acute rejection, with similar implications for graft function as acute perivascular rejection.
Alemtuzumab in the Treatment of Refractory Acute Rejection and Bronchiolitis Obliterans Syndrome After Human Lung Transplantation
  • B. D. Reams, L. Musselwhite, S. Palmer
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2007
TLDR
First evidence is provided that alemtuzumab is a potentially useful therapy in lung transplant recipients with RAR or BOS, as a humanized anti‐CD52 antibody which results in potent lymphocyte depletion is utilized.
...
1
2
3
4
5
...